Logo image of ARMP

ARMATA PHARMACEUTICALS INC (ARMP) Stock Fundamental Analysis

NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD

2.105  +0.1 (+4.73%)

Fundamental Rating

2

ARMP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ARMP may be in some trouble as it scores bad on both profitability and health. ARMP shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARMP had negative earnings in the past year.
In the past year ARMP has reported a negative cash flow from operations.
In the past 5 years ARMP always reported negative net income.
In the past 5 years ARMP always reported negative operating cash flow.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ARMP's Return On Assets of -42.11% is in line compared to the rest of the industry. ARMP outperforms 53.46% of its industry peers.
Industry RankSector Rank
ROA -42.11%
ROE N/A
ROIC N/A
ROA(3y)-47.31%
ROA(5y)-54.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200

1.3 Margins

ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARMP remains at a similar level compared to 1 year ago.
The number of shares outstanding for ARMP has been increased compared to 5 years ago.
Compared to 1 year ago, ARMP has a worse debt to assets ratio.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -6.91, we must say that ARMP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARMP (-6.91) is worse than 68.21% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.91
ROIC/WACCN/A
WACC8.91%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

ARMP has a Current Ratio of 0.19. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
ARMP has a Current ratio of 0.19. This is amonst the worse of the industry: ARMP underperforms 97.34% of its industry peers.
ARMP has a Quick Ratio of 0.19. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.19, ARMP is doing worse than 96.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

ARMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.97%, which is quite impressive.
The Revenue has grown by 34.66% in the past year. This is a very strong growth!
Measured over the past years, ARMP shows a very strong growth in Revenue. The Revenue has been growing by 76.77% on average per year.
EPS 1Y (TTM)25.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)34.66%
Revenue growth 3Y76.77%
Revenue growth 5YN/A
Sales Q2Q%142.69%

3.2 Future

The Earnings Per Share is expected to grow by 14.28% on average over the next years. This is quite good.
ARMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.82% yearly.
EPS Next Y46.17%
EPS Next 2Y1.82%
EPS Next 3Y15.36%
EPS Next 5Y14.28%
Revenue Next Year42.1%
Revenue Next 2Y19.2%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 200 -200 400 600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARMP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

ARMP's earnings are expected to grow with 15.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.82%
EPS Next 3Y15.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (2/21/2025, 8:04:00 PM)

2.105

+0.1 (+4.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners3.84%
Inst Owner Change0.24%
Ins Owners0.75%
Ins Owner Change0%
Market Cap76.16M
Analysts82.86
Price Target7.14 (239.19%)
Short Float %0.17%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.59%
Min EPS beat(2)47.48%
Max EPS beat(2)155.7%
EPS beat(4)2
Avg EPS beat(4)7.73%
Min EPS beat(4)-118.22%
Max EPS beat(4)155.7%
EPS beat(8)3
Avg EPS beat(8)-7.06%
EPS beat(12)5
Avg EPS beat(12)-6.21%
EPS beat(16)8
Avg EPS beat(16)-3.24%
Revenue beat(2)1
Avg Revenue beat(2)61.93%
Min Revenue beat(2)-100%
Max Revenue beat(2)223.86%
Revenue beat(4)2
Avg Revenue beat(4)46.04%
Min Revenue beat(4)-100%
Max Revenue beat(4)223.86%
Revenue beat(8)3
Avg Revenue beat(8)8.57%
Revenue beat(12)5
Avg Revenue beat(12)11.12%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)6.86%
EPS NY rev (3m)6.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)83.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.15
BVpS-1.41
TBVpS-1.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.31%
ROA(5y)-54.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 352.47%
Cap/Sales 79.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -6.91
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)399.1%
Cap/Depr(5y)257.49%
Cap/Sales(3y)83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y46.17%
EPS Next 2Y1.82%
EPS Next 3Y15.36%
EPS Next 5Y14.28%
Revenue 1Y (TTM)34.66%
Revenue growth 3Y76.77%
Revenue growth 5YN/A
Sales Q2Q%142.69%
Revenue Next Year42.1%
Revenue Next 2Y19.2%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.82%
EBIT growth 1Y0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.29%
OCF growth 3YN/A
OCF growth 5YN/A